Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol

BACKGROUND: Two main therapies, pazopanib and sunitinib, are used in the first-line setting for metastatic renal cell carcinoma (mRCC). These two tyrosine kinase inhibitors (TKI) are equally effective in terms of survival; however, they frequently induce adverse events. In this setting, Health-Relat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Health Qual Life Outcomes
Hlavní autoři: Mouillet, Guillaume, Fritzsch, Joëlle, Paget-Bailly, Sophie, Pozet, Astrid, Es-Saad, Ikram, Meurisse, Aurelia, Vernerey, Dewi, Mouyabi, Kristina, Berthod, Diane, Bonnetain, Franck, Anota, Amélie, Thiery-Vuillemin, Antoine
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Study Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360763/
https://ncbi.nlm.nih.gov/pubmed/30717745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12955-019-1085-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky